Adipokines in the HIV/HAART-associated lipodystrophy syndrome

Metabolism: Clinical and Experimental

Volumn 62, Issue 9, 2013, Pages 1199-1205

  Paruthi, Jason ^a,b   Gill, Natasha ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Adiponectin; HALS; HIV; Leptin; Lipodystrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FAT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METRELEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIOGLITAZONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENERGY EXPENDITURE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INCREASED APPETITE; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIPOATROPHY; LIPOHYPERTROPHY; MACROPHAGE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LYMPHOMA; VIRUS LOAD;

EID: 84883173171     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.04.014     Document Type: Review

References (95)

1. F.E. McCutchan Global epidemiology of HIV J Med Virol 78 Suppl 1 2006 S7 S12
2. M. Dybul, A.S. Fauci, and J.G. Bartlett Guidelines for using antiretroviral agents among HIV-infected adults and adolescents Ann Intern Med 137 5 Pt 2 2002 381 433
3. D.C. Borato, G.C. Parabocz, and S.R. Ribas Changes of metabolic and inflammatory markers in HIV infection: glucose, lipids, serum hs-CRP and myeloperoxidase Metabolism 61 10 2012 1353 1360
4. M.K.S. Leow, C.L. Addy, and C.S. Mantzoros Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies J Clin Endocrinol Metab 88 5 2003 1961 1976
5. S. Grinspoon, and A. Carr Cardiovascular risk and body-fat abnormalities in HIV-infected adults N Engl J Med 352 1 2005 48 62
6. D. Dimock, V. Thomas, and A. Cushing Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood Metabolism 60 6 2011 874 880
7. V.A. Triant, J.B. Meigs, and S.K. Grinspoon Association of C-reactive protein and HIV infection with acute myocardial infarction J Acquir Immune Defic Syndr 51 3 2009 268 273
8. V.A. Triant, S. Regan, and H. Lee Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system J Acquir Immune Defic Syndr 55 5 2010 615 619
9. S.W. Worm, C. Sabin, and R. Weber Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (d:A:D) study J Infect Dis 201 3 2010 318 330
10. C.G. Fiorenza, S.H. Chou, and C.S. Mantzoros Lipodystrophy: pathophysiology and advances in treatment Nat Rev Endocrinol 7 3 2011 137 150
11. J.C. Shlay, S. Sharma, and G. Peng The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy J Acquir Immune Defic Syndr 51 3 2009 298 304
12. V. Estrada, M. Serrano-Rios, and M.T. Martinez Larrad Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy J Acquir Immune Defic Syndr 29 1 2002 32 40
13. G.S. Nagy, S. Tsiodras, and L.D. Martin Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin Clin Infect Dis 36 6 2003 795 802
14. M. Savès, F. Raffi, and J. Capeau Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy Clin Infect Dis 34 10 2002 1396 1405
15. J. Yao, W. Yu, and T. Li The pilot study of DXA assessment in Chinese HIV-infected men with clinical lipodystrophy J Clin Densitom 14 1 2011 58 62
16. C. Hadigan, S. Borgonha, and J. Rabe Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy Metabolism 51 9 2002 1143 1147
17. K.V. Fitch, L.M. Guggina, and H.M. Keough Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects Metabolism 58 5 2009 608 615
18. F. Villarroya, P. Domingo, and M. Giralt Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment Biochim Biophys Acta 1801 3 2010 392 399
19. S.B. Haugaard, O. Andersen, and I. Halsall Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution Metabolism 56 7 2007 939 946
20. M.G. van Vonderen, R.M. Blumer, and E.A. Hassink Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine- containing compared with NRTI-sparing combination antiretroviral therapy J Acquir Immune Defic Syndr 53 2 2010 186 193
21. J. Chaparro, D.N. Reeds, and W. Wen Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy Metabolism 54 5 2005 561 567
22. R. Roche, I. Poizot-Martin, and C.M. Yazidi Effects of antiretroviral drug combinations on the differentiation of adipocytes AIDS 16 1 2002 13 20
23. R.L. Divi, K.J. Haverkos, and J.A. Humsi Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to zidovudine Environ Mol Mutagen 48 3-4 2007 179 189
24. A. Maagaard, and D. Kvale Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity Scand J Infect Dis 41 11-12 2009 808 817
25. R.H. Haubrich, S.A. Riddler, and A.G. DiRienzo Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment AIDS 23 9 2009 1109 1118
26. S. Shrivastav, T. Kino, and T. Cunningham Human immunodeficiency virus (HIV)-1 viral protein r suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy Mol Endocrinol 22 2 2008 234 247
27. H. Rose, I. Woolley, and J. Hoy Hiv infection and high-density lipoprotein: the effect of the disease vs the effect of treatment Metabolism 55 1 2006 90 95
28. S.H. Han, B.S. Chin, and H.S. Lee Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy Metabolism 58 11 2009 1523 1529
29. O.M. Adeyemi, S. Vibhakar, and A.T. Evans Obesity and lymphocyte subsets in virologically suppressed HIV-infected patients Metabolism 58 9 2009 1285 1287
30. R. Rossi, A. Nuzzo, and G. Guaraldi Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients Metabolism 58 7 2009 927 933
31. S.B. Haugaard, O. Andersen, and S.B. Pedersen Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy Metabolism 55 2 2006 175 182
32. S. Tsiodras, K.A. Poulia, and M. Yannakoulia Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy Metabolism 58 6 2009 854 859
33. C. Hadigan, J. Rabe, and S. Grinspoon Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance J Clin Endocrinol Metab 87 10 2002 4611 4615
34. S.I. Anghel, E. Bedu, and C.D. Vivier Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma J Biol Chem 282 41 2007 29946 29957
35. R. Kohli, A. Shevitz, and S. Gorbach A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy HIV Med 8 7 2007 420 426
36. A. Carr, C. Workman, and D. Carey No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial Lancet 363 9407 2004 429 438
37. V. Simha, S. Rao, and A. Garg Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety Diabetes Obes Metab 10 12 2008 1275 1276
38. R.V. Sekhar, S.G. Patel, and S. D'Amico Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study Metabolism 60 6 2011 754 760
39. M. Caron, M. Auclair, and C. Vigouroux The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance Diabetes 50 6 2001 1378 1388
40. H. Yamamoto, S. Kurebayashi, and T. Hirose Reduced IRS-2 and GLUT4 expression in PPARgamma2-induced adipocytes derived from C/EBPbeta and C/EBPdelta-deficient mouse embryonic fibroblasts J Cell Sci 115 Pt 18 2002 3601 3607
41. T. Takamura, E. Nohara, and Y. Nagai Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3 t3-l1 adipocytes Eur J Pharmacol 422 1-3 2001 23 29
42. A. Gavrila, W. Hsu, and S. Tsiodras Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial Clin Infect Dis 40 5 2005 745 749
43. C.L. Addy, A. Gavrila, and S. Tsiodras Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy J Clin Endocrinol Metab 88 2 2003 627 636
44. L.L. Sweeney, A.M. Brennan, and C.S. Mantzoros The role of adipokines in relation to HIV lipodystrophy AIDS 21 8 2007 895 904
45. Y.H. Lee, F. Magkos, and C.S. Mantzoros Effects of leptin and adiponectin on pancreatic beta-cell function Metabolism 60 12 2011 1664 1672
46. T. Yamauchi, J. Kamon, and Y. Ito Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 423 6941 2003 762 769
47. J. Fruebis, T.S. Tsao, and S. Javorschi Proteolytic cleavage product of 30-kda adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice Proc Natl Acad Sci USA 98 4 2001 2005 2010
48. T. Kadowaki, and T. Yamauchi Adiponectin and adiponectin receptors Endocr Rev 26 3 2005 439 451
49. W.A. Haque, I. Shimomura, and Y. Matsuzawa Serum adiponectin and leptin levels in patients with lipodystrophies J Clin Endocrinol Metab 87 5 2002 2395
50. Q. Tong, J.-L. Sankalé, and C.M. Hadigan Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices J Clin Endocrinol Metab 88 4 2003 1559 1564
51. C. Vigouroux, M. Maachi, and T.-H. NguyÃan Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy AIDS 17 10 2003 1503 1511
52. P. Pisto, O. Ukkola, and M. Santaniemi Plasma adiponectin - an independent indicator of liver fat accumulation Metabolism 60 11 2011 1515 1520
53. L.H. Duntas, V. Popovic, and G. Panotopoulos Adiponectin: novelties in metabolism and hormonal regulation Nutr Neurosci 7 4 2004 195 200
54. T.A. Dardeno, S.H. Chou, and H.S. Moon Leptin in human physiology and therapeutics Front Neuroendocrinol 31 3 2010 377 393
55. C.S. Mantzoros The role of leptin in human obesity and disease: a review of current evidence Ann Intern Med 130 8 1999 671 680
56. C. Bjorbaek, and B.B. Kahn Leptin signaling in the central nervous system and the periphery Recent Prog Horm Res 59 2004 305 331
57. J.S. Flier Clinical review 94: what's in a name? In search of leptin's physiologic role J Clin Endocrinol Metab 83 5 1998 1407 1413
58. J.M. Friedman, and J.L. Halaas Leptin and the regulation of body weight in mammals Nature 395 6704 1998 763 770
59. I. Shimomura, R.E. Hammer, and S. Ikemoto Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy Nature 401 6748 1999 73 76
60. K. Ebihara, Y. Ogawa, and H. Masuzaki Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes Diabetes 50 6 2001 1440 1448
61. C.S. Mantzoros Role of leptin in reproduction Ann N Y Acad Sci 900 2000 174 183
62. O.P. Hamnvik, X. Liu, and M. Petrou Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: The Cyprus metabolism prospective cohort study Metabolism 60 7 2011 987 993
63. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152(2): 93-9100.
64. J.K. Kim, O. Gavrilova, and Y. Chen Mechanism of insulin resistance in A-ZIP/F-1 fatless mice J Biol Chem 275 12 2000 8456 8460
65. W.T. Donahoo, N.R. Stob, and S. Ammon Leptin increases skeletal muscle lipoprotein lipase and postprandial lipid metabolism in mice Metabolism 60 3 2011 438 443
66. J.L. Chan, G. Matarese, and G.K. Shetty Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans Proc Natl Acad Sci USA 103 22 2006 8481 8486
67. E. Sienkiewicz, F. Magkos, and K.N. Aronis Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women Metabolism 60 9 2011 1211 1221
68. C.M. Gordon Leptin and the skeleton - where is the fat? Metabolism 60 9 2011 1203 1206
69. K.F. Petersen, E.A. Oral, and S. Dufour Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy J Clin Invest 109 10 2002 1345 1350
70. E.D. Javor, E.K. Cochran, and C. Musso Long-term efficacy of leptin replacement in patients with generalized lipodystrophy Diabetes 54 7 2005 1994 2002
71. E.A. Oral, V. Simha, and E. Ruiz Leptin-replacement therapy for lipodystrophy N Engl J Med 346 8 2002 570 578
72. J.H. Lee, J.L. Chan, and E. Sourlas Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy J Clin Endocrinol Metab 91 7 2006 2605 2611
73. K. Mulligan, H. Khatami, and J.-M. Schwarz The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia J Clin Endocrinol Metab 94 4 2009 1137 1144
74. C. Hadigan, C. Corcoran, and N. Basgoz Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial JAMA 284 4 2000 472 477
75. C. Hadigan, S. Yawetz, and A. Thomas Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial Ann Intern Med 140 10 2004 786 794
76. J. Lo, S.M. You, and B. Canavan Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial JAMA 300 5 2008 509 519
77. A.Y. Chong, B.C. Lupsa, and E.K. Cochran Efficacy of leptin therapy in the different forms of human lipodystrophy Diabetologia 53 1 2010 27 35
78. R.V. Sekhar, F. Jahoor, and D. Iyer Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome Metabolism 61 10 2012 1395 1403
79. E.D. Javor, S.A. Moran, and J.R. Young Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy J Clin Endocrinol Metab 89 7 2004 3199 3207
80. D.B. Savage, and S. O'Rahilly Leptin therapy in lipodystrophy Diabetologia 53 1 2010 7 9
81. E.A. Oral, and J.L. Chan Rationale for leptin-replacement therapy for severe lipodystrophy Endocr Pract 16 2 2010 324 333
82. C.S. Mantzoros W(h)ither metreleptin for lipodystrophy and the metabolic syndrome? Endocr Pract 2010 1 18
83. F. Magkos, A. Brennan, and L. Sweeney Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study Metabolism 60 7 2011 1045 1049
84. A.M. Brennan, J.H. Lee, and S. Tsiodras R-methuleptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating igf and igf-binding protein levels: observational and interventional studies in humans Eur J Endocrinol 160 2 2009 173 176
85. M.N. Rao, K. Mulligan, and V. Tai Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance J Clin Endocrinol Metab 95 9 2010 4361 4366
86. C. Wanke, J. Gerrior, and J. Kantaros Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV AIDS 13 15 1999 2099 2103
87. C. Grunfeld, M. Thompson, and S.J. Brown Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy J Acquir Immune Defic Syndr 45 3 2007 286 297
88. M. Bickel, S. Zangos, and V. Jacobi A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy HIV Med 7 6 2006 397 403
89. C.S. Mantzoros, S. Moschos, and I. Avramopoulos Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans J Clin Endocrinol Metab 82 10 1997 3408 3413
90. J.P. Foo, and C.S. Mantzoros Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: a need for more mechanistic studies and large, randomized, placebo-controlled trials Metabolism 61 10 2012 1331 1336
91. F. Magkos, and C.S. Mantzoros Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment Metabolism 60 6 2011 749 753
92. C.S. Mantzoros, F. Magkos, and M. Brinkoetter Leptin in human physiology and pathophysiology Am J Physiol Endocrinol Metab 301 4 2011 E567 E584
93. S. Tsiodras, and C. Mantzoros Leptin and adiponectin in the HIV associated metabolic syndrome: physiologic and therapeutic implications Am J Infect Dis 2 3 2006 141 152
94. Y. Daali, V. Ancrenaz, and M. Bosilkovska Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients Metabolism 60 11 2011 1584 1589
95. S. Tsiodras, and C.S. Mantzoros Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future Metabolism 60 11 2011 1497 1499